- Home
- FSFG vs ZNTL Comparison
FSFG vs ZNTL Comparison
Compare FSFG & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FSFG | ZNTL |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | N/A | 166 |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 221.5M | 190.4M |
| IPO Year | 2008 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FSFG | ZNTL |
|---|---|---|
| Price | $31.86 | $2.82 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $31.50 | $5.87 |
| AVG Volume (30 Days) | 11.3K | ★ 2.5M |
| Earning Date | 01-28-2026 | 11-10-2025 |
| Dividend Yield | ★ 1.98% | N/A |
| EPS Growth | ★ 67.68 | N/A |
| EPS | ★ 3.32 | N/A |
| Revenue | ★ $84,223,000.00 | $26,865,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.76 | ★ N/A |
| Revenue Growth | ★ 23.59 | N/A |
| 52 Week Low | $21.63 | $1.01 |
| 52 Week High | $34.10 | $3.95 |
Technical Indicators
Market Signals| Indicator | FSFG | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 51.24 | 58.30 |
| Support Level | $31.81 | $2.80 |
| Resistance Level | $34.10 | $3.29 |
| Average True Range (ATR) | 0.54 | 0.46 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 37.07 | 56.40 |
Price Performance
Historical ComparisonAbout FSFG First Savings Financial Group Inc.
First Savings Financial Group Inc provides various banking services to individuals and business customers in southern Indiana. The bank accepts deposits from the general public & uses those funds, along with other borrowings, mainly to originate a residential mortgage, commercial mortgage, construction, commercial business, & consumer loans, and to a lesser extent, to invest in mortgage-backed securities and other debt securities. The company conducts lending and deposit activities mainly with individuals and small businesses in its market area. The bank operates in two segments: core banking, which accounts for the majority of revenue, and SBA lending.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.